NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EDIT

Editas Medicine Inc

Jun 23 • 11:34AM ET

2.16

Dollar change -0.06
Percentage change -2.80	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM BLUE SGMO VERV RARE PSTX CLLS QURE

| Held by: IWM VTI VXF IWN IBB DFAT SCHA VTWO VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.04	Insider Own	0.91%	Shs Outstand	83.71M	Perf Week	9.53%
Market Cap	180.63M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-4.99%	Shs Float	82.95M	Perf Month	43.85%
Enterprise Value	-9.20M	PEG	-	EPS next Q	-0.39	Inst Own	54.29%	Short Float	10.85%	Perf Quarter	64.72%
Income	-251.23M	P/S	5.04	EPS this Y	34.40%	Inst Trans	-13.76%	Short Ratio	4.29	Perf Half Y	41.96%
Sales	35.84M	P/B	2.89	EPS next Y	42.87%	ROA	-71.37%	Short Interest	9.00M	Perf YTD	69.91%
Book/sh	0.75	P/C	0.82	EPS next 5Y	27.74%	ROE	-140.82%	52W High	6.05 -64.33%	Perf Year	-57.19%
Cash/sh	2.64	P/FCF	-	EPS past 3/5Y	-0.38% -1.48%	ROIC	-312.51%	52W Low	0.91 137.09%	Perf 3Y	-79.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.15% 9.50%	Gross Margin	82.37%	Volatility	7.53% 6.22%	Perf 5Y	-93.01%
Dividend TTM	-	EV/Sales	-0.26	EPS Y/Y TTM	-44.70%	Oper. Margin	-578.30%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.08	Sales Y/Y TTM	-48.37%	Profit Margin	-701.06%	RSI (14)	59.72	Recom	2.57
Dividend Gr. 3/5Y	- -	Current Ratio	3.08	EPS Q/Q	-21.18%	SMA20	10.72%	Beta	2.09	Target Price	3.25
Payout	-	Debt/Eq	0.50	Sales Q/Q	310.40%	SMA50	30.20%	Rel Volume	1.12	Prev Close	2.22
Employees	246	LT Debt/Eq	0.29	Earnings	May 12 AMC	SMA200	4.92%	Avg Volume	2.10M	Price	2.16
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-63.12% 625.66%	Trades		Volume	828,771	Change	-2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12

Show Previous Ratings

Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	Loading…
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Loading…
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
09:00AM	Loading…
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%
Nov-06-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.13%
Nov-05-24 01:59PM	Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty (GuruFocus.com) +8.33%
Nov-04-24 08:40AM	Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:36AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Editas Medicine Announces Third Quarter 2024 Results and Business Updates (GlobeNewswire)
Oct-31-24 03:55AM	Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? (Insider Monkey)
Oct-25-24 10:00AM	Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 12:13PM	Editas and Genevant team up to develop gene editing therapies (Pharmaceutical Technology) -12.50%
07:15AM	Editas, changing course again, looks to partner lead CRISPR therapy (BioPharma Dive)
07:00AM	Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update (GlobeNewswire)
Oct-21-24 04:30PM	Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics (GlobeNewswire) +11.90%
Oct-18-24 04:01PM	Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept (GlobeNewswire)
Oct-17-24 05:01PM	State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings (GuruFocus.com)
Oct-05-24 06:27AM	Editas Medicine Secures $57M Deal for Gene-Editing Technology (TipRanks)
Oct-04-24 07:13PM	Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m (Pharmaceutical Technology) +5.62% -5.03%
07:33AM	Editas trades Vertex fees for upfront cash in DRI deal (BioPharma Dive)
Oct-03-24 06:00PM	Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust (GlobeNewswire)
Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)
03:39AM	Q2 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:05AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -12.18%
07:07AM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Second Quarter 2024 Results and Business Updates (GlobeNewswire)
Jul-31-24 07:00AM	Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-17-24 11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace) +5.01%
Jun-29-24 08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 09:04AM	What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential? (Insider Monkey)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-25-24 08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-17-24 08:13AM	Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies (Zacks)
Jun-14-24 03:01AM	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.83%
03:00AM	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire)
Jun-07-24 11:30AM	Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-22-24 07:05PM	EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (GuruFocus.com) +9.26%
May-14-24 07:01PM	Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (GuruFocus.com) +5.63%
04:27PM	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing (MT Newswires)
10:00AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June (GlobeNewswire)
May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parison Amy	SVP, Chief Financial Officer	Jun 03 '25	Sale	1.72	446	769	17,506	Jun 04 06:39 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	1.72	726	1,252	69,519	Jun 04 06:37 PM
O'Neill Gilmore Neil	CEO	Jun 03 '25	Sale	1.72	15,192	26,196	280,282	Jun 04 06:36 PM
O'Neill Gilmore Neil	Officer	Jun 03 '25	Proposed Sale	1.87	20,000	37,400		Jun 02 05:32 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	Mar 04 '25	Sale	1.71	4,109	7,030	112,720	Mar 05 04:44 PM
O'Neill Gilmore Neil	CEO	Mar 04 '25	Sale	1.71	16,632	28,452	295,474	Mar 05 04:43 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 04 '25	Sale	1.71	2,891	4,946	70,245	Mar 05 04:41 PM
O'Neill Gilmore Neil	Officer	Mar 03 '25	Proposed Sale	1.86	35,000	65,100		Feb 28 04:40 PM
Lucera Erick	Officer	Mar 03 '25	Proposed Sale	1.86	8,000	14,880		Feb 28 04:39 PM
Burkly Linda	Officer	Mar 03 '25	Proposed Sale	1.86	6,000	11,160		Feb 28 04:35 PM
O'Neill Gilmore Neil	CEO	Dec 03 '24	Sale	2.08	1,618	3,361	312,106	Dec 05 04:40 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Dec 03 '24	Sale	2.08	541	1,124	133,354	Dec 05 04:37 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Sep 04 '24	Sale	3.42	518	1,774	133,895	Sep 06 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 04 '24	Sale	3.42	1,555	5,325	313,724	Sep 06 04:18 PM
O'Neill Gilmore Neil	Officer	Sep 03 '24	Proposed Sale	3.92	3,000	11,760		Aug 29 04:19 PM
Mei Baisong	Officer	Sep 03 '24	Proposed Sale	3.92	1,000	3,920		Aug 29 04:17 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 25 '24	Sale	5.42	11,886	64,370	73,136	Jul 26 05:02 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jul 19 '24	Sale	5.21	6,619	34,456	134,413	Jul 22 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience